लोड हो रहा है...
Profile of nintedanib in the treatment of solid tumors: the evidence to date
Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevacizumab, a monoclonal antibody that targets vascular endothelial growth factor (VEGF), was the first antiangiogenic agent approve...
में बचाया:
| में प्रकाशित: | Onco Targets Ther |
|---|---|
| मुख्य लेखकों: | , |
| स्वरूप: | Artigo |
| भाषा: | Inglês |
| प्रकाशित: |
Dove Medical Press
2015
|
| विषय: | |
| ऑनलाइन पहुंच: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4677757/ https://ncbi.nlm.nih.gov/pubmed/26677336 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S78805 |
| टैग : |
टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!
|